The positive clinical results from the BRACELET-1 study, showing improved overall survival and response rates, are likely to boost investor confidence in Oncolytics Biotech. The fact that the median overall survival was not reached is a significant achievement, indicating the potential effectiveness of the treatment. This news is directly related to Oncolytics Biotech and is important for investors as it may lead to increased interest and potential stock price appreciation.